REG - Diaceutics PLC - Block Listing Return

DiaceuticsAnnouncement

05/04/2024 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240405:nRSE5465Ja&default-theme=true

RNS Number : 5465J  Diaceutics PLC  05 April 2024

 

Diaceutics PLC

 

BLOCK LISTING RETURN

 

 

Belfast and London, 5 April 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and bitech industry
industry, gives the below information required by Schedule 6 of the AIM Rules
for Companies in connection with the the UK and Global Share Incentive Plan
for employees (the "SIP") and the Employee Share Option Plan (the "ESOP")
which includes long term incentive awards.

 

 

 Name of applicant:                                                              Diaceutics PLC
 Name of scheme:                                                                 UK and Global Share Incentive Plan for employees (the "SIP") and the Employee
                                                                                 Share Option Plan (the "ESOP") which includes long term incentive awards.
 Period of return:                       From:                                   6 October 2023              To:                         6 April 2024
 Balance under scheme from previous return:                                      1,500,000 Ordinary Shares of £0.002 each
 The amount by which the block scheme has been increased, if the scheme has      N/A
 been increased since the date of the last return:
 Number of securities issued/allotted under schemes during period:               46,440 Ordinary Shares

 Balance under scheme not yet issued/allotted at end of period                   1,453,560  Ordinary Shares
 Number and class of securities originally listed and the date of admission      1,500,000  Ordinary Shares on 6 October 2023
 Total number of securities in issue at the end of the period                    84,696,786 Ordinary Shares of £0.002 each
 Name of contact:                                                                Nick Roberts
 Telephone number of contact:                                                    As below

 

 

 

 

Enquiries:

 

 Diaceutics PLC                                         Tel: +44 (0)28 9040 6500
 Ryan Keeling, Chief Executive Officer                  investorrelations@diaceutics.com
 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network®.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock
Exchange. RNS is approved by the Financial Conduct Authority to act as a
Primary Information Provider in the United Kingdom. Terms and conditions
relating to the use and distribution of this information may apply. For
further information, please contact rns@lseg.com (mailto:rns@lseg.com)  or
visit www.rns.com (http://www.rns.com/) .

RNS may use your IP address to confirm compliance with the terms and
conditions, to analyse how you engage with the information contained in this
communication, and to share such analysis on an anonymised basis with others
as part of our commercial services. For further information about how RNS and
the London Stock Exchange use the personal data you provide us, please see
our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) .

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRLELFBZZLXBBK